Specific functional effects of memantine treatment in patients with moderate to severe Alzheimer's disease
Abstract
Treatment of Alzheimer's disease (AD) that combats progressive functional deterioration can improve the patient's quality of life and reduce caregiver burden. Memantine, a moderate affinity N-methyl-D-aspartate receptor antagonist, reduces global deterioration in AD patients and provides cognitive and functional benefits relative to placebo. Two previous studies reported statistically significant benefits of memantine for overall functional ability on the Alzheimer Disease Cooperative Study Activities of Daily Living Inventory modified for severe dementia (ADCS-ADL(19)), Functional Assessment Staging, and G2 scale. The present study reports a single-item analysis of the ADL scales from the two trials and shows that patients treated with memantine demonstrated a numerical advantage over placebo on all items assessed. These results help to translate the positive effects of memantine into specific aspects of functional ability, information that is relevant to AD patients and their families as well as to researchers interested in the assessment of functional ability in AD clinical trials.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several randomized controlled trials of 12 to 50 weeks duration and supported by meta-analyses.
“In moderate and severe AD, short-term efficacy of memantine monotherapy compared with placebo is reported in several RCTs of 12 to 50 weeks duration and supported by meta-analyses.”
From The Alzheimer’s Disease Clinical Spectrum (2019) · cites this paper as [102]
Cites
McKhann, G., Drachman, D., Folstein, M., Katzman, R., Price, D., & Stadlan, E. M. (1984) · Neurology · doi:10.1212/wnl.34.7.939 · Cited by 27,915 · see citing works
Excitatory Amino Acids as a Final Common Pathway for Neurologic Disorders
Epstein, F. H., Lipton, S. A., & Rosenberg, P. A. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403033300907 · Cited by 2,644 · see citing works
Memantine in Moderate-to-Severe Alzheimer's Disease
Reisberg, B., Doody, R., Stöffler, A., Schmitt, F., Ferris, S., & Möbius, H. J. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa013128 · Cited by 2,043 · see citing works
Self-citationTariot, P. N., Farlow, M. R., Grossberg, G. T., Graham, S. M., McDonald, S., Gergel, I., & for the Memantine Study Group (2004) · JAMA · doi:10.1001/jama.291.3.317 · Cited by 1,403 · see citing works
An Inventory to Assess Activities of Daily Living for Clinical Trials in Alzheimerʼs Disease
Galasko, D., Bennett, D. A., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. H. (1997) · Alzheimer Disease & Associated Disorders · doi:10.1097/00002093-199700112-00005 · Cited by 1,198 · see citing works
Galasko, D. R., Bennett, D., Sano, M., Ernesto, C., Thomas, R., Grundman, M., & Ferris, S. H. (1997) · PubMed · Cited by 767 · see citing works
To: A 24-week, randomized, double-blind study of donepezil in moderate to severe Alzheimer’s disease
(2001) · Neurology · doi:10.1212/wnl.57.11.2153-a · Cited by 490 · see citing works
Danysz, W., & Parsons, C. G. (2003) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.938 · Cited by 404 · see citing works
Parsons, C. G., Quack, G., Bresink, I., Baran, L., Przegaliński, E., Kostowski, W., Krząścik, P., Hartmann, S., & Danysz, W. (1995) · Neuropharmacology · doi:10.1016/0028-3908(95)00092-k · Cited by 311 · see citing works
Feldman, H., Gauthier, S. G., Hecker, J. R., Vellas, B. J., Emir, B., Mastey, V., Subbiah, P., & The Donepezil MSAD Study Investigators Group (2003) · Journal of the American Geriatrics Society · doi:10.1046/j.1365-2389.2003.51260.x · Cited by 202 · see citing works
Wimo, A. B., Winblad, B. G., Stöffler, A., Wirth, Y., & Moebius, H. J. (2003) · PharmacoEconomics · doi:10.2165/00019053-200321050-00004 · Cited by 165 · see citing works
Self-citationTolerability of memantine in combination with cholinesterase inhibitors in dementia therapy
Hartmann, S., & bius, H. J. R. M. (2003) · International Clinical Psychopharmacology · doi:10.1097/00004850-200303000-00003 · Cited by 82 · see citing works
Tolerability of memantine in combination with cholinesterase inhibitors in dementia therapy.
Hartmann, S., & Möbius, H. J. (2003) · PubMed · doi:10.1097/01.yic.0000054279.38655.74 · Cited by 72 · see citing works
Self-citationBehavioural Activities in Demented Geriatric Patients
Ferm, L. (2009) · Gerontologia Clinica · doi:10.1159/000245521 · Cited by 55 · see citing works
Glutamate receptors as a target for Alzheimer’s disease — are clinical results supporting the hope?
Winblad, B. G., Möbius, H. J., & Stöffler, A. (2002) · Journal of neural transmission. Supplementum · doi:10.1007/978-3-7091-6139-5_20 · Cited by 33 · see citing works
Self-citationvan der Kam, P., & Hoeksma, B. H. (1989) · PubMed · Cited by 7 · see citing works
Winblad (1999) · doi:10.1002/(sici)1099-1166(199902)14:2
Flagged first, then by citations
Cited by
Sorted by citations
Glutamate receptor ion channels.
Mayer, M. (2005) · Current Opinion in Neurobiology · doi:10.1016/j.conb.2005.05.004 · Cited by 163 · see citing works
Glutamate Receptor Ion Channels: Structure, Regulation, and Function
Traynelis, S. F., Wollmuth, L. P., McBain, C. J., Menniti, F. S., Vance, K. M., Ogden, K. K., Hansen, K. B., Yuan, H., Myers, S. J., & Dingledine, R. (2010) · Pharmacological Reviews · doi:10.1124/pr.109.002451 · Cited by 3,568 · see citing works
McShane, R., Areosa Sastre, A., & Minakaran, N. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub5 · Cited by 1,155 · see citing works
Parsons, C. G., Stöffler, A., & Danysz, W. (2007) · Neuropharmacology · doi:10.1016/j.neuropharm.2007.07.013 · Cited by 701 · see citing works
The Alzheimer’s Disease Clinical Spectrum
Atri, A. (2019) · Medical Clinics of North America · doi:10.1016/j.mcna.2018.10.009 · Cited by 623 · see citing works
McShane, R., Westby, M. J., Roberts, E., Minakaran, N., Schneider, L., Farrimond, L. E., Maayan, N., Ware, J., & Debarros, J. (2019) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd003154.pub6 · Cited by 310 · see citing works
Current and future treatments in Alzheimer’s disease
Atri, A. (2019) · Seminars in Neurology · doi:10.1055/s-0039-1678581 · Cited by 309 · see citing works
Memantine in Moderate to Severe Alzheimer’s Disease: a Meta-Analysis of Randomised Clinical Trials
Winblad, B. G., Jones, R. W., Wirth, Y., Stöffler, A., & Möbius, H. J. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000102568 · Cited by 253 · see citing works
Self-citationDementia patients caregivers quality of life: the PIXEL study
Thomas, P., Lalloué, F., Preux, P., Hazif‐Thomas, C., Pariel, S., Inscale, R., Belmin, J., & Clément, J. (2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1422 · Cited by 235 · see citing works
Yu, S. P., Jiang, M. Q., Shim, S. S., Pourkhodadad, S., & Wei, L. (2023) · Molecular Neurodegeneration · doi:10.1186/s13024-023-00636-1 · Cited by 165 · see citing works
Detailed assessment of activities of daily living in moderate to severe Alzheimer's disease
Galasko, D. R., Schmitt, F. A., Thomas, R. G., Jin, S., Bennett, D., & Ferris, S. H. (2005) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617705050502 · Cited by 158 · see citing works
Self-citationADDLs and the signaling web that leads to Alzheimer’s disease
Krafft, G. A., & Klein, W. L. (2010) · Neuropharmacology · doi:10.1016/j.neuropharm.2010.07.012 · Cited by 111 · see citing works
Cognitive Enhancers (Nootropics). Part 1: Drugs Interacting with Receptors
Froestl, W., Muhs, A., & Pfeifer, A. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2012-121186 · Cited by 91 · see citing works
Efficacy and Safety of Memantine in Moderate-to-Severe Alzheimer Disease: The Evidence to Date
Bullock, R. (2006) · Alzheimer Disease & Associated Disorders · doi:10.1097/01.wad.0000201847.29836.a5 · Cited by 89 · see citing works
Regulation of neural cell survival by HIV-1 infection
Jones, G. J., & Power, C. (2005) · Neurobiology of Disease · doi:10.1016/j.nbd.2005.07.018 · Cited by 86 · see citing works
McKeage, K. (2009) · CNS Drugs · doi:10.2165/11201020-000000000-00000 · Cited by 84 · see citing works
Wilkinson, D. G., & Andersen, H. F. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000105162 · Cited by 84 · see citing works
Memantine in dementia: a review of the current evidence
Herrmann, N., Li, A., & Lanctôt, K. L. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.558006 · Cited by 69 · see citing works
Persons With Moderate Alzheimer's Disease Improve Activities and Mood via Instruction Technology
Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Sigafoos, J., MT, P., Megna, M., Zonno, N., Martire, M. L. L., Pinto, K., & Minervini, M. G. (2009) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317509332627 · Cited by 51 · see citing works
Rammsayer, T. H. (2006) · Brain Research · doi:10.1016/j.brainres.2005.12.019 · Cited by 47 · see citing works
Lancioni, G. E., Martire, M. L. L., Singh, N. N., O’Reilly, M. F., Sigafoos, J., Pinto, K., & Minervini, M. G. (2008) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317508328181 · Cited by 46 · see citing works
Olin, J. T., Bhatnagar, V., Reyes, P. F., Koumaras, B., Meng, X., & Brannan, S. K. (2009) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.2355 · Cited by 42 · see citing works
Lancioni, G. E., Pinto, K., Martire, M. L. L., Tota, A., Rigante, V., Tatulli, E., Pansini, E., Minervini, M. G., Singh, N. N., O’Reilly, M. F., et al. (2008) · Disability and Rehabilitation · doi:10.1080/09638280801906438 · Cited by 42 · see citing works
Riepe, M. W., Adler, G., Ibach, B., Weinkauf, B., Tracik, F. M., & Günay, İ. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000100875 · Cited by 34 · see citing works
The measuring, meaning and importance of activities of daily living (ADLs) as an outcome
Rockwood, K. J. (2007) · International Psychogeriatrics · doi:10.1017/s1041610207004966 · Cited by 34 · see citing works
Li, W., Marta Kutas, A., Gray, J. A., Hagerman, R. J., & Olichney, J. (2020) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2020.09.023 · Cited by 27 · see citing works
Lancioni, G., Singh, N., O’Reilly, M., Zonno, N., Flora, A., Cassano, G., De Vanna, F., De Bari, A. L., Pinto, K., & Minervini, M. (2009) · Developmental Neurorehabilitation · doi:10.1080/17518420903029493 · Cited by 26 · see citing works
Management of moderate to severe Alzheimer’s disease: Focus on memantine
Dominguez, E., Chin, T., Chen, C., & Wu, T. (2011) · Taiwanese Journal of Obstetrics and Gynecology · doi:10.1016/j.tjog.2011.10.004 · Cited by 25 · see citing works
Barreto, P. D. S., Denormandie, P., Lepage, B., Armaingaud, D., Rapp, T., Chauvin, P., Vellas, B. J., & Rolland, Y. (2016) · Contemporary Clinical Trials · doi:10.1016/j.cct.2016.02.004 · Cited by 17 · see citing works
Dekker, M. J. H. J., Bouvy, J. C., O'Rourke, D., Thompson, R., Makady, A., Jonsson, P. F., & Wied, C. C. G. (2019) · Frontiers in Medicine · doi:10.3389/fmed.2019.00073 · Cited by 17 · see citing works
Lancioni, G. E., Singh, N. N., O’Reilly, M. F., Zonno, N., Cassano, G., Vanna, F. D., Bari, A. L. D., Pinto, K., & Minervini, M. G. (2010) · Developmental Neurorehabilitation · doi:10.3109/17518420903468480 · Cited by 17 · see citing works
Hong, Y. J., Choi, S. H., Jeong, J. H., Park, K. W., & Na, H. R. (2018) · Journal of Alzheimer s Disease · doi:10.3233/jad-180159 · Cited by 15 · see citing works
Memantine in moderate to severe Alzheimer’s disease: an observational post-marketing study
Rainer, M. K., Wuschitz, A., Jagsch, C., Erb, C., Chirikdjian, J.-J., & Mucke, H. A. (2011) · Journal of Neural Transmission · doi:10.1007/s00702-011-0623-8 · Cited by 12 · see citing works
Cente, M., Mandakova, S., & Filipčík, P. (2009) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-009-9379-1 · Cited by 11 · see citing works
Added Therapeutic Value of Memantine in the Treatment of??Moderate to Severe Alzheimer??s Disease
Heinen-Kammerer, T., Rulhoff, H., Nelles, S., & Rychlik, R. P. T. (2006) · Clinical Drug Investigation · doi:10.2165/00044011-200626060-00001 · Cited by 10 · see citing works
Drug Class Review on Alzheimer's Drugs
Hansen, R. A., Kaufer, D. J., Lohr, K. N., Carey, T., & Sheps, C. G. (2006) · Cited by 9 · see citing works
Paskavitz, J., Gunstad, J., & Samuel, J. (2007) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317506294474 · Cited by 5 · see citing works
Allain, H., Bentué‐Ferrer, D., & Lacomblez, L. (2004) · PubMed · Cited by 4 · see citing works
Arrieta, J. M. L. (2006) · Revista Española de Geriatría y Gerontología · doi:10.1016/s0211-139x(06)72950-x · Cited by 2 · see citing works
Clinical Experience of Memantine in Alzheimer’s Disease
Blesa, R. (2008) · European Neurological Review · doi:10.17925/enr.2008.03.02.22 · Cited by 2 · see citing works
Pedersen, W. A. (2007) · xPharm: The Comprehensive Pharmacology Reference · doi:10.1016/b978-008055232-3.60662-2 · Cited by 1 · see citing works
HIV treatment: mechanisms of neurotoxicity and implications for targeted therapy
Lu, Y., & Wu (2012) · Neurobehavioral HIV Medicine · doi:10.2147/nbhiv.s24914
HIV-1 Infection and Cell Death in the Nervous System
Jones, G. J., & Power, C. (2005) · CRC Press eBooks · doi:10.1201/9781420038156.ch22
Феномен эксайтотоксичности как объект фармакологического воздействия при деменциях
Burchynskyi, S. H. (2016) · INTERNATIONAL NEUROLOGICAL JOURNAL · doi:10.22141/2224-0713.1.79.2016.73990
Mechanisms of NMDA receptor inhibition by memantine and ketamine
Glasgow, N. G. (2016) · D-Scholarship@Pitt (University of Pittsburgh)
Psychopharmacologic Agents to Enhance Cognition in Alzheimer’s Disease
Atri, A., & Stern, T. A. (2015) · Psychiatric Annals · doi:10.3928/00485713-20150626-07
Current awareness in human psychopharmacology
(2005) · Human Psychopharmacology Clinical and Experimental · doi:10.1002/hup.633
Current awareness in geriatric psychiatry
(2005) · International Journal of Geriatric Psychiatry · doi:10.1002/gps.1222
Anderson, H. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.99471-6
Anderson, H. S. (2015) · Elsevier eBooks · doi:10.1016/b978-0-12-801238-3.05297-1
Наумовская, Н. А., Лелявко, И. А., Голубева, Т. С., Startsev, A. I., & Докукина, Т. В. (2020) · Неврология и нейрохирургия Восточная Европа · doi:10.34883/pi.2020.10.1.052
Novell, R., Esteban, S., Ribas, N., Chaler, R., Baró, N. C., Paniello, N., & Mariscot, C. (2008) · Hispana
- Authors
- Doody, R., Wirth, Y., Schmitt, F., & Möbius, H. J.
- Affiliations
- Baylor College of Medicine (US)
- Merz (Germany) (DE)
- University of Kentucky (US)
- ORCID
- Schmitt, F.
- Venue
- Dementia and Geriatric Cognitive Disorders
- Publisher
- S. Karger AG
- Published
- 2004
- Volume
- 18
- Issue
- 2
- Pages
- 227-232
- ISSN
- 1420-8008 (ISSN-L)
- 1421-9824
- OpenAlex
- W2070531209
- Cited by
- 52
- References
- 16
- Citations by year
- 2023: 1 · 2020: 2 · 2019: 4 · 2018: 1 · 2016: 3 · 2015: 3 · 2012: 2
- FWCI
- 4.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Dementia and Geriatric Cognitive Disorders (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Merz Pharmaceuticals
- National Institute on Aging (U19AG010483)
- Topics
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Physiology › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Pharmacology › Cholinesterase and Neurodegenerative Diseases
- Keywords
- memantine, Alzheimer's disease, functional capacity, activities of daily living, NMDA receptor antagonists, functional decline, caregiver burden, quality of life, clinical trial endpoints
- MeSH terms
- Activities of Daily Living, Aged, Alzheimer Disease, Double-Blind Method, Europe, Female, Humans, Male, Memantine, Mental Status Schedule, Social Behavior, United States, Multicenter Studies as Topic, Randomized Controlled Trials as Topic, Treatment Outcome, Caregivers, Cost of Illness, Excitatory Amino Acid Antagonists, Nootropic Agents
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
